Please reload

Recent Posts

Virtuvax for collaboration on your innovation in vaccine development or your biosimilar

May 12, 2017

Please reload

Featured Posts

Virtuvax to attend DCVMN in Kunming

September 19, 2018

Virtuvax consults in vaccine development and provides biosimilar and vaccine technologies. A most recent one, is the prefusion RSV-F vaccine technology. If you are interested, I would be most interested to meet you at the developing countries vaccine manufacturers network (DCVMN) annual meeting in Kunming, China, from October 29 - 31 2018.  



Tags: vaccine development, disruptive technology, biosimilar, monoclonal antibody, vaccine technology, DCVMN, Kunming, vaccine consultancy, RSV, pre-fusion RSV-F, RSV vaccine, pneumococcal vaccine





Please reload

Follow Us